Clinical Trial Update: SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study [Phase 3]

View source ↗

Summary

This clinical trial update covers a Phase III dose-justification and gadoteridol-controlled comparative study of SH L 562BB for brain metastases. Results were p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases

Drugs mentioned

• GADOTERIDOL (GADOTERIDOL)
• SH L 562BB

Snippet

Sponsor: Bayer | Conditions: Brain Metastases | Phase 3 | Status: COMPLETED | Results posted: 2011-08-03